IBDEI12U ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39105,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,39105,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,39105,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,39106,0)
 ;;=D47.1^^148^1947^51
 ;;^UTILITY(U,$J,358.3,39106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39106,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,39106,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,39106,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,39107,0)
 ;;=C82.69^^148^1947^52
 ;;^UTILITY(U,$J,358.3,39107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39107,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39107,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,39107,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,39108,0)
 ;;=C82.60^^148^1947^53
 ;;^UTILITY(U,$J,358.3,39108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39108,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,39108,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,39108,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,39109,0)
 ;;=D56.2^^148^1947^54
 ;;^UTILITY(U,$J,358.3,39109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39109,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,39109,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,39109,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,39110,0)
 ;;=D75.9^^148^1947^55
 ;;^UTILITY(U,$J,358.3,39110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39110,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,39110,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,39110,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,39111,0)
 ;;=D59.0^^148^1947^58
 ;;^UTILITY(U,$J,358.3,39111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39111,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,39111,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,39111,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,39112,0)
 ;;=D59.2^^148^1947^59
 ;;^UTILITY(U,$J,358.3,39112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39112,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,39112,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,39112,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,39113,0)
 ;;=R59.9^^148^1947^62
 ;;^UTILITY(U,$J,358.3,39113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39113,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,39113,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,39113,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,39114,0)
 ;;=D47.3^^148^1947^63
 ;;^UTILITY(U,$J,358.3,39114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39114,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,39114,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,39114,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,39115,0)
 ;;=C82.09^^148^1947^64
 ;;^UTILITY(U,$J,358.3,39115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39115,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39115,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,39115,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,39116,0)
 ;;=C82.00^^148^1947^65
 ;;^UTILITY(U,$J,358.3,39116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39116,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,39116,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,39116,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,39117,0)
 ;;=C82.19^^148^1947^66
 ;;^UTILITY(U,$J,358.3,39117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39117,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39117,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,39117,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,39118,0)
 ;;=C82.10^^148^1947^67
 ;;^UTILITY(U,$J,358.3,39118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39118,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,39118,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,39118,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,39119,0)
 ;;=C82.29^^148^1947^68
 ;;^UTILITY(U,$J,358.3,39119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39119,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39119,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,39119,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,39120,0)
 ;;=C82.20^^148^1947^69
 ;;^UTILITY(U,$J,358.3,39120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39120,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,39120,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,39120,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,39121,0)
 ;;=C82.39^^148^1947^70
 ;;^UTILITY(U,$J,358.3,39121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39121,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39121,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,39121,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,39122,0)
 ;;=C82.30^^148^1947^71
 ;;^UTILITY(U,$J,358.3,39122,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39122,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,39122,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,39122,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,39123,0)
 ;;=C82.49^^148^1947^72
 ;;^UTILITY(U,$J,358.3,39123,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39123,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39123,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,39123,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,39124,0)
 ;;=C82.40^^148^1947^73
 ;;^UTILITY(U,$J,358.3,39124,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39124,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,39124,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,39124,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,39125,0)
 ;;=C82.99^^148^1947^74
 ;;^UTILITY(U,$J,358.3,39125,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39125,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39125,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,39125,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,39126,0)
 ;;=C82.90^^148^1947^75
 ;;^UTILITY(U,$J,358.3,39126,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39126,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,39126,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,39126,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,39127,0)
 ;;=R59.1^^148^1947^60
 ;;^UTILITY(U,$J,358.3,39127,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39127,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,39127,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,39127,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,39128,0)
 ;;=C91.40^^148^1947^79
 ;;^UTILITY(U,$J,358.3,39128,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39128,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39128,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,39128,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,39129,0)
 ;;=C91.42^^148^1947^77
 ;;^UTILITY(U,$J,358.3,39129,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39129,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,39129,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,39129,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,39130,0)
 ;;=C91.41^^148^1947^78
 ;;^UTILITY(U,$J,358.3,39130,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39130,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,39130,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,39130,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,39131,0)
 ;;=D57.01^^148^1947^80
 ;;^UTILITY(U,$J,358.3,39131,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39131,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,39131,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,39131,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,39132,0)
 ;;=D57.00^^148^1947^81
 ;;^UTILITY(U,$J,358.3,39132,1,0)
 ;;=^358.31IA^4^2
